Cargando…
An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications
Typically, antibody–drug conjugates (ADCs) are made up of a humanized antibody and a small-molecule medication connected by a chemical linker. ADCs’ ability to deliver cytotoxic agents to the specific site with reduced side effects showed promising results in oncology. To date, fourteen ADCs have be...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385119/ https://www.ncbi.nlm.nih.gov/pubmed/37513995 http://dx.doi.org/10.3390/pharmaceutics15071807 |
_version_ | 1785081324907790336 |
---|---|
author | Pal, Lal Bahadur Bule, Prajakta Khan, Wahid Chella, Naveen |
author_facet | Pal, Lal Bahadur Bule, Prajakta Khan, Wahid Chella, Naveen |
author_sort | Pal, Lal Bahadur |
collection | PubMed |
description | Typically, antibody–drug conjugates (ADCs) are made up of a humanized antibody and a small-molecule medication connected by a chemical linker. ADCs’ ability to deliver cytotoxic agents to the specific site with reduced side effects showed promising results in oncology. To date, fourteen ADCs have been approved by the US Food and Drug Administration, and approximately 297 ADCs are in pre-clinical/clinical stages in the oncology area. Inspired by these outcomes, a few scientists explored the potential of antibody–drug conjugates in non-oncological conditions such as arthritis, myasthenia gravis, immunological disorders, and kidney failure. However, there are limited data available on the non-oncological applications of antibody–drug conjugates. This current review focuses on the non-oncological applications of antibody–drug conjugates, their developmental studies, testing procedures, in vitro evaluations, and pre-clinical testing. Additionally, a summary of the restrictions, difficulties, and prospects for ADCs in non-oncological applications is provided. |
format | Online Article Text |
id | pubmed-10385119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103851192023-07-30 An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications Pal, Lal Bahadur Bule, Prajakta Khan, Wahid Chella, Naveen Pharmaceutics Review Typically, antibody–drug conjugates (ADCs) are made up of a humanized antibody and a small-molecule medication connected by a chemical linker. ADCs’ ability to deliver cytotoxic agents to the specific site with reduced side effects showed promising results in oncology. To date, fourteen ADCs have been approved by the US Food and Drug Administration, and approximately 297 ADCs are in pre-clinical/clinical stages in the oncology area. Inspired by these outcomes, a few scientists explored the potential of antibody–drug conjugates in non-oncological conditions such as arthritis, myasthenia gravis, immunological disorders, and kidney failure. However, there are limited data available on the non-oncological applications of antibody–drug conjugates. This current review focuses on the non-oncological applications of antibody–drug conjugates, their developmental studies, testing procedures, in vitro evaluations, and pre-clinical testing. Additionally, a summary of the restrictions, difficulties, and prospects for ADCs in non-oncological applications is provided. MDPI 2023-06-24 /pmc/articles/PMC10385119/ /pubmed/37513995 http://dx.doi.org/10.3390/pharmaceutics15071807 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pal, Lal Bahadur Bule, Prajakta Khan, Wahid Chella, Naveen An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications |
title | An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications |
title_full | An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications |
title_fullStr | An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications |
title_full_unstemmed | An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications |
title_short | An Overview of the Development and Preclinical Evaluation of Antibody–Drug Conjugates for Non-Oncological Applications |
title_sort | overview of the development and preclinical evaluation of antibody–drug conjugates for non-oncological applications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385119/ https://www.ncbi.nlm.nih.gov/pubmed/37513995 http://dx.doi.org/10.3390/pharmaceutics15071807 |
work_keys_str_mv | AT pallalbahadur anoverviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications AT buleprajakta anoverviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications AT khanwahid anoverviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications AT chellanaveen anoverviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications AT pallalbahadur overviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications AT buleprajakta overviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications AT khanwahid overviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications AT chellanaveen overviewofthedevelopmentandpreclinicalevaluationofantibodydrugconjugatesfornononcologicalapplications |